AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season

Rhea-AI Summary

SAN DIEGO, July 26, 2022 – AXIM Biotechnologies, Inc. (OTCQB: AXIM) announced the launch of an enhanced rapid Ocular Immunoglobulin E (IgE) test, responding to climate change-driven trends in allergy seasons. A recent study indicates that allergy seasons are becoming longer and starting earlier. AXIM's optimized IgE test offers results 50% faster, aiding the diagnosis of allergic conjunctivitis, affecting 40% of the U.S. population annually. CEO John W. Huemoeller II emphasized the need for improved diagnostic tools to handle the increasing prevalence of ocular allergies as seasons change.

Positive

• AXIM's enhanced rapid IgE test provides results 50% faster than previous versions, improving patient throughput.
• The test targets an increasing prevalence of allergic conjunctivitis, supported by a significant portion of the U.S. population affected annually.

Negative

• No guarantees that the diagnostic candidate will receive FDA approval or generate significant revenue.

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has launched an enhanced version of its rapid Ocular Immunoglobulin E (IgE) test in response to a study recently published in Nature by researchers at the University of Michigan Department of Climate and Space Sciences and Engineering.

The article titled “Projected climate-driven changes in pollen emission season length and magnitude over the continental United States” showcases that climate change is making allergy season occur sooner and for a longer period of time than in recent years. Spring pollen emissions are projected to begin 10 to 40 days earlier and last five to 15 days longer in the summer and fall.

This is important to know because allergic conjunctivitis, allergic reactions caused by airborne allergens, has become increasingly prevalent. But even though approximately 40% of the U.S. population experiences it annually, it is severely underdiagnosed due to the industry’s lack of diagnostic tools.

AXIM’s enhanced rapid IgE test helps in the assessment of total tear IgE levels and is useful for the clinical diagnosis of allergic conjunctivitis and its severity. The test has been optimized to provide results nearly 50% faster than the non-optimized IgE test with no loss in sensitivity or specificity. This change will result in quicker patient throughput and give physicians the ability to test more patients per day in the same amount of time.

“It’s becoming clear that the intensity and frequency of ocular allergies will only increase as we experience longer allergy seasons here in the U.S.,” said John W. Huemoeller II, Chief Executive Officer of AXIM® Biotech. “Our goal is to make it possible for doctors to keep up with these changes and diagnose and treat double the number of patients suffering from allergic conjunctivitis than they can with their current diagnostic tools.”

To learn more about AXIM’s eyecare division and products, please visit https://aximeye.com/.

About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease. For more information, please visit www.AXIMBiotech.com.

Forward-Looking Statements
The statements made by Axim Biotechnologies, Inc. in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will ever be approved for use by the U.S. FDA or any equivalent foreign regulatory agency. Further, Axim’s eye care diagnostic products that are FDA cleared may not be manufactured in large enough quantities or that third parties with established eye care physicians will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidates are successful, they may generate only limited revenue and profits for the Company. Various other factors are detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on April 15, 2022, and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc. undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

CONTACT
Public Relations
Kathryn Brown, Account Director
CMW Media
P. 858-221-8001
kathryn@cmwmedia.com

AXIM Corporate
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA
P. 858-923-4422

Investor Relations
investors@aximbiotech.com
888-759-0844 

FAQ

What is AXIM Biotechnologies' new product?

AXIM has launched an enhanced rapid Ocular Immunoglobulin E (IgE) test.

How much faster is the new IgE test from AXIM?

The enhanced IgE test provides results nearly 50% faster compared to previous versions.

Why is AXIM's rapid IgE test important?

It addresses the increasing prevalence of allergic conjunctivitis, which affects about 40% of the U.S. population annually.

What impact does climate change have on allergies according to AXIM?

Climate change is leading to longer and earlier allergy seasons, increasing the need for effective diagnostic tools.

What are the potential risks mentioned by AXIM regarding their diagnostics?

There is no assurance that AXIM's diagnostic candidates will receive FDA approval or generate significant revenue.